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ORIGINAL ARTICLE: EARLY PREGNANCYSupplementation with progestogens
in the ﬁrst trimester of pregnancy to
prevent miscarriage in women with
unexplained recurrent miscarriage: a
systematic review and meta-analysis
of randomized, controlled trials
Gabriele Saccone, M.D.,a Corina Schoen,M.D.,b JasonM. Franasiak, M.D.,c Richard T. Scott, Jr., M.D., H.C.L.D.,c
and Vincenzo Berghella, M.D.b
a Department of Neuroscience, Reproductive Sciences and Dentistry, School of Medicine, University of Naples Federico II,
Naples, Italy; b Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, Sidney Kimmel Medical
College of Thomas Jefferson University, Philadelphia, Pennsylvania; and c Reproductive Medicine Associates of New
Jersey, Morristown, New JerseyObjective: To investigate whether treatment with progestogens in the ﬁrst trimester of pregnancy would decrease the incidence of
miscarriage in women with a history of unexplained recurrent miscarriage.
Design: Systematic review and meta-analysis.
Setting: Not applicable.
Patient(s): Women with a history of unexplained recurrent miscarriage.
Intervention(s): Randomized, controlled trials were identiﬁed by searching electronic databases. We included randomized, controlled
trials comparing supplementation with progestogens (i.e., intervention group) in the ﬁrst trimester of pregnancy with control (either
placebo or no treatment) in women with a history of recurrent miscarriage. All types of progestogens, including natural P and synthetic
progestins, were analyzed.
Main Outcome Measure(s): The primary outcome was the incidence of miscarriage. The summary measures were reported as relative
risk (RR) with 95% conﬁdence interval (CI).
Result(s): Ten trials including 1,586 women with recurrent miscarriage were analyzed. Eight studies used placebo as control and were
double-blind. Regarding the intervention, two RCTs used natural P, whereas the other eight studies used progestins:
medroxyprogesterone, cyclopentylenol ether of progesterone, dydrogesterone, or 17-hydroxyprogesterone caproate. Pooled data
from the 10 trials showed that women with a history of unexplained recurrent miscarriage who were randomized to the
progestogens group in the ﬁrst trimester and before 16 weeks had a lower risk of recurrent miscarriage (RR 0.72, 95% CI 0.53–0.97)
and higher live birth rate (RR 1.07, 95% CI 1.02–1.15) compared with those who did not. No statistically signiﬁcant differences were
found in the other secondary outcomes, including preterm birth (RR 1.09, 95% CI 0.71–1.66), neonatal mortality (RR 1.80, 95% CI
0.44–7.34), and fetal genital abnormalities (RR 1.68, 95% CI 0.22–12.62).
Conclusion(s): Our ﬁndings provide evidence that supplementation with progestogens may reduce the incidence of recurrent miscar-
riages and seem to be safe for the fetuses. Synthetic progestogens, including weekly IM 17-hydroxyprogesterone caproate, but not
natural P, were associated with a lower risk of recurrent miscarriage. Given the limitations of the studies included in our meta-
analysis, it is difﬁcult to recommend route and dose of progestogen therapy. Further head-to-head trials of P types, dosing, and
route of administration are required. (Fertil Steril 2017;107:430–8. 2016 by American Society for Reproductive Medicine.)
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Fertility and Sterility®R ecurrent miscarriage (or recurrent pregnancy loss) isdeﬁned by the American Society for ReproductiveMedicine as the loss of two or more pregnancies before
24 weeks (1, 2). It affects approximately 1% to 2% of women
who attempt to have a child (1, 2). Unexplained recurrent
miscarriage is associated with substantial adverse clinical
and psychological consequences for women and their
families (1–3). Various therapeutic strategies to increase the
rate of live births among these women have been evaluated,
but no effective treatment has been identiﬁed (1–3).
Progestogens (or progestagens or gestagens), including P,
are a class of steroid hormones essential to achieve and main-
tain a healthy pregnancy.(4) The efﬁcacy of P therapy has
been studied in several populations (5, 6), including women
with prior preterm birth (7), women with short cervical
length (8), women with threatened miscarriage (9), and as
maintenance tocolysis in women with arrested preterm
labor (10, 11). However, the efﬁcacy of P supplementation
in the ﬁrst trimester of pregnancy among women with a
history of recurrent miscarriage is still a matter of debate
(1–3, 12).
The aim of this systematic review and meta-analysis of
randomized, controlled trials (RCTs) was to investigate
whether treatment with progestogens in the ﬁrst trimester
of pregnancy would decrease the incidence of miscarriage
in women with a history of unexplained recurrent
miscarriage.MATERIALS AND METHODS
Eligibility Criteria
The review protocol was established by two investigators
(G.S., V.B.) before commencement and was registered with
the PROSPERO International Prospective Register of System-
atic Reviews (registration no. CRD42016033721).
Two authors (G.S., V.B.) identiﬁed trials by searching
independently the electronic databases MEDLINE, Scopus,
ClinicalTrials.gov, the PROSPERO International Prospective
Register of Systematic Reviews, EMBASE, Scielo, and the Co-
chrane Central Register of Controlled Trials with the use of a
combination of text words: ‘‘progesterone,’’ ‘‘miscarriage,’’
‘‘progesteron,’’ ‘‘recurrent,’’ ‘‘pregnancy,’’ ‘‘progestogens,’’
‘‘progestagens,’’ ‘‘gestagens,’’ ‘‘loss,’’ ‘‘vaginal,’’ ‘‘termination
of pregnancy,’’ ‘‘17P,’’ ‘‘17-OHPC,’’ ‘‘hydroxyprogesterone,’’
‘‘caproate,’’ ‘‘alpha,’’ ‘‘injection’’ ‘‘trial,’’ ‘‘gel,’’ ‘‘singleton,’’
‘‘multiple,’’ and ‘‘habitual’’ from inception of each databases
until January 2016. No restrictions for language or
geographic location were applied. In addition, the reference
lists of all identiﬁed articles were examined to identify studies
not captured by electronic searches.Study Selection
We included RCTs comparing supplementation with proges-
togens (i.e., intervention group) in the ﬁrst trimester of preg-
nancy with control (either placebo or no treatment) in women
with a history of recurrent miscarriage, either consecutive or
nonconsecutive. The deﬁnition of recurrent miscarriage was
per the original trial design, which included either two orVOL. 107 NO. 2 / FEBRUARY 2017more or three or more losses. Trials in which recurrent miscar-
riage was deﬁned as one miscarriage or more were excluded.
All progestogens types were included, both natural P and syn-
thetic progestogens (i.e., progestins), including but not limited
to 17-a-hydroxyprogesterone-caproate (17-OHPC) and dy-
drogesterone. Studies in women with threatened miscarriage
were excluded.Data Extraction and Risk of Bias Assessment
The risk of bias in each included study was assessed by using
the criteria outlined in the Cochrane Handbook for Systematic
Reviews of Interventions (13). Seven domains related to risk
of bias were assessed in each included trial because there is
evidence that these issues are associated with biased estimates
of treatment effect: [1] random sequence generation; [2] allo-
cation concealment; [3] blinding of participants and
personnel; [4] blinding of outcome assessment; [5] incomplete
outcome data; [6] selective reporting; and [7] other bias. Re-
view authors' judgments were categorized as ‘‘low risk,’’
‘‘high risk,’’ or ‘‘unclear risk’’ of bias (13).
Two authors (G.S., V.B.) independently assessed inclusion
criteria, risk of bias, and data extraction. Disagreements were
resolved by consensus. Data from each eligible study were ex-
tracted without modiﬁcation of original data onto custom-
made data collection forms. Differences were reviewed and
further resolved by common review of the entire process.
Primary and secondary outcomes were deﬁned before
data extraction. The primary outcome was the incidence of
miscarriage, as deﬁned by the authors. Secondary outcomes
included incidence of live birth, as deﬁned by the authors;
preterm birth in women without miscarriage (i.e., preterm de-
livery<37 weeks); neonatal mortality (deﬁned as a death of a
live-born baby within the ﬁrst 28 days of life); and fetal gen-
ital abnormalities/virilization. We planned to assess the pri-
mary outcome (i.e., incidence of miscarriage) in planned
subgroup analyses classifying whole trials by interaction tests
as described by the Cochrane Handbook for Systematic Review
of Interventions (13). The subgroup analyses entailed [1]
placebo-controlled trials only; [2] route of administration of
progestogen: oral, intramuscular, or vaginal; [3] type of pro-
gestogens: natural P or synthetic progestins; [4] type of pro-
gestogens: natural P, medroxyprogesterone, cyclopentyl enol
ether of P, dydrogesterone, or 17-OHPC; and [5] deﬁnition of
recurrent miscarriage: two or more or three or more losses.
Only the primary outcome (i.e., incidence of miscarriage)
was used in the subgroup analyses.Data Analysis
The data analysis was completed independently by two au-
thors (G.S., V.B.) using Review Manager 5.3 (The Nordic Co-
chrane Centre, Cochrane Collaboration, 2014) (13). The
completed analyses were then compared, and any difference
was resolved with review of the entire data and independent
analysis. Statistical heterogeneity between studies was as-
sessed using the Higgins I2 statistic (13). In case of statistically
signiﬁcant heterogeneity (moderate (70% % I2 R 50%) to
high (I2 R70%) heterogeneity) the random effect model of431
TABLE 1
Studies assessed for the eligibility criteria.
First author and year (reference) Included/excluded Reason for exclusion
Swyer 1953 (29) Included –
Shearman 1963 (22) Included –
Le Vine 1964 (28) Included –
Goldzieher 1964 (26) Included –
Klopper 1965 (18) Included –
Moller 1965 (9) Excluded Inclusion criteria: All women with positive pregnancy test
MacDonald 1972 (19) Included –
Berle 1980 (15) Excluded Inclusion criteria: Women presenting with threatened miscarriage,
deﬁned as bleeding up to 20 wk
Tognoni 1980 (23) Excluded Inclusion criteria: Women presenting with threatened miscarriage,
deﬁned as bleeding up to 14 wk
Gerhard 1987 (17) Excluded Inclusion criteria: Women presenting with threatened miscarriage,
deﬁned as bleeding up to 20 wk
Reijnders 1988 (21) Included –
Corrado 2002 (16) Excluded Inclusion criteria: Women undergoing amniocentesis
Nyboe Anderson 2002 (20) Excluded Inclusion criteria: All women having undergone assisted reproductive
technology
El-Zibdeh 2005 (25) Included –
Kumar 2014 (27) Included –
Coomarasamy 2015 (24) Included –
Saccone. Progestogens for miscarriage. Fertil Steril 2016.
ORIGINAL ARTICLE: EARLY PREGNANCYDerSimonian and Laird was used to obtain the pooled risk es-
timate. In cases of no inconsistency in the risk estimate (I2
<50%) a ﬁxed effect model was managed (13). The summary
measures were reported as relative risk (RR) with 95% conﬁ-
dence interval (CI), with an RR <1 indicating treatment
beneﬁt. Potential publication biases were assessed graphically
by using the funnel plot of the primary outcome and statisti-
cally by using Begg's and Egger's tests (13). A P value of< .05
was considered statistically signiﬁcant.
The meta-analysis was reported according to the
Preferred Reporting Item for Systematic Reviews and Meta-
analyses (PRISMA) statement (14).RESULTS
Study Selection and Study Characteristics
Supplemental Figure 1 (available online) shows the ﬂow dia-
gram (PRISMA template) of information through the different
phases of the review. Sixteen trials were assessed for eligibility
(Table 1) (9, 15–29). Six studies were excluded (9, 15–17, 20,
23). Ten randomized trials including 1,586 women with
recurrent miscarriage were analyzed (18, 19, 21, 22, 24–29).
None of the included studies had high risk of bias in
‘‘selective reporting’’ and ‘‘allocation concealment’’ (selection
bias). Eight studies were double-blind (Supplemental Fig. 2)
(18, 19, 21, 22, 24, 26–28). Supplemental Figure 3 shows the
funnel plot of the primary outcome for assessing publication
bias; the symmetric plot suggests no publication bias.
Publication bias, assessed using Begg's and Egger's tests,
showed no signiﬁcant bias (P¼ .79 and P¼ .73, respectively).
Table 2 shows the characteristics of the included trials. All
studies had incidence of recurrent miscarriage as primary
outcome. Only one study excluded women who had experi-
enced a live birth (18). Eight trials only accepted women
within the ﬁrst trimester of pregnancy (18, 19, 21, 22, 24,43225, 27, 29), whereas Le Vine et al. (28) accepted women to
the 20th gestational week. It was unclear in the remaining
study what gestational cutoff, if any, was used (26).
In one trial participants were excluded from randomiza-
tion if they had antiphospholipid syndrome or other recog-
nized thrombophilia conditions, as well as uterine cavity
abnormalities or other identiﬁable cause of recurrent miscar-
riage, such as diabetes, thyroid disease, or systematic lupus
erythematous; or if they were currently receiving heparin
therapy or had contraindications to P use (24).
Six trials deﬁned recurrent miscarriage as history of three
or more miscarriage (24–29), four as history of two or more
miscarriage (18, 19, 21, 22). Five RCTs came from the
United Kingdom (18, 19, 22, 24, 29), two from the United
States (26, 28), one from India (27), one from the
Netherlands (21), and one from Jordan (25).
Eight studies used placebo as control (18, 19, 21, 22, 24,
26–28). Regarding the intervention, two RCTs used natural
P (24, 29), whereas the other eight studies used progestins
(i.e., synthetic progestogens) (18, 19, 21, 22, 25–28). One
trial used 6  25-mg natural P pellets inserted within the
gluteal muscle (29), two used 17-OHPC 500 mg weekly IM
(21, 28), one a dosing scale of 17-OHPC (22), two used dydro-
gesterone 10 mg two times daily orally (25, 27), one used
cyclopentyl enol ether of P 50 mg twice daily orally (18),
one used 2 5-mg tablets of dydrogesterone three times daily
(19), and one used medroxyprogesterone 10 mg daily (26),
whereas Coomarasamy et al. (24) randomized women to
receive twice-daily vaginal suppositories containing either
400 mg of micronized P or matched placebo. In all 10 trials
the intervention started soon after the pregnancy was
conﬁrmed and not later the ﬁrst trimester.
Data regarding the use of heparin and/or aspirin were
only described in one study (24). Coomarasamy et al. re-
ported the use of aspirin in 75 women (38 in the P groupVOL. 107 NO. 2 / FEBRUARY 2017
TABLE 2
Characteristics of the included trials.
First author
and year
(reference)
Study
location
No. of
patients at
randomization
Inclusion
criteria and
deﬁnition of
recurrent
miscarriage
Deﬁnition of
miscarriage
Deﬁnition
of live birth
GA at
randomization Intervention Control
Duration of
intervention
Primary
outcome
Swyer
1953 (29)
United
Kingdom
47 (27/20) Women with
three or
more prior
consecutive
miscarriages
Pregnancy
loss before
22 wk
Delivery of a
live infant
after 22 wk
As soon as
pregnancy
conﬁrmed
and not
later than
10th wk
6  25-mg natural P
pellets inserted
within the gluteal
muscle
No
treatment
Unclear Miscarriage
Shearman
1963 (22)
United
Kingdom
50 (27/23) Women with
two or
more prior
consecutive
miscarriages
Pregnancy
loss before
21 wk
Delivery of a
live infant
after 21 wk
As soon as
pregnancy
conﬁrmed
and not
later than
12th wk
17P IM
Up to 8 wk: 250 mg/wk
8–11 wk: 375 mg/wk
12–16 wk: 500 mg/wk
17–20 wk: 375 mg/wk
21–24 wk: 250 mg/wk
Placebo Until
miscarriage
or the
24th wk
Miscarriage
Le Vine
1964 (28)
US 30 (15/15) Women with
three or
more prior
consecutive
miscarriages
Pregnancy
loss before
21 wk
Delivery of a
live infant
after 21 wk
Within the
16th wk
17P 500 mg/wk IM Placebo Until
miscarriage
or the
36th wk
Miscarriage
Goldzieher
1964 (26)
US 18 (8/10) Women with
two or
more prior
consecutive
miscarriages
Pregnancy
loss before
22 wk
Delivery of a
live infant
after 22 wk
Within the
14th wk
Medroxyprogesterone
10 mg/daily oral
Placebo Unclear Miscarriage
Klopper
1965 (18)
United
Kingdom
33 (18/15) Women with
two or
more prior
consecutive
miscarriages
Pregnancy
loss before
22 wk
Delivery of a
live infant
after 22 wk
As soon as
pregnancy
conﬁrmed
and not
later than
10th wk
Cyclopentyl
enol ether
of P 50 mg
BID oral
Placebo Unclear Miscarriage
MacDonald
1972 (19)
United
Kingdom
40 (20/20) Women with
two or
more prior
consecutive
miscarriages
Pregnancy
loss before
22 wk
Delivery of a
live infant
after 22 wk
Unclear 2  5-mg
oral tablets
of dydrogesterone
3 times daily
Placebo Unclear Miscarriage
Reijnders
1988 (21)
Netherlands 64 (32/32) Women with
two or
more prior
consecutive or
nonconsecutive
miscarriage
Pregnancy
loss before
24 wk
Delivery of a
live infant
after 24 wk
As soon as
pregnancy
conﬁrmed
and not
later than
6th wk
17P 500 mg/wk IM Placebo From the
7th wk to
the 12th wk
Miscarriage
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TABLE 2
Continued.
First author
and year
(reference)
Study
location
No. of
patients at
randomization
Inclusion
criteria and
deﬁnition of
recurrent
miscarriage
Deﬁnition of
miscarriage
Deﬁnition
of live birth
GA at
randomization Intervention Control
Duration of
intervention
Primary
outcome
El-Zibdeh
2005 (25)
Jordan 130 (82/48) Women <35 y
with three
or more prior
consecutive
miscarriages
Pregnancy
loss before
24 wk
Delivery of a
live infant
after 24 wk
As soon as
pregnancy
conﬁrmed
Dydrogesterone
10 mg BID
oral until 12 wk
No
treatment
Until
miscarriage
or the
12th wk
Miscarriage
Kumar
2014 (27)
India 348 (175/173) Women with
three or
more prior
consecutive
miscarriages
Pregnancy
loss before
14 wk
– As soon as
pregnancy
conﬁrmed
and not
later than
10th wk
Dydrogesterone
10 mg BID oral
Placebo Until
miscarriage
or the
20th wk
Miscarriage
Coomarasamy
2015 (24)
United
Kingdom
826 (398/428) Women with
three or
more prior
consecutive or
nonconsecutive
miscarriages
Pregnancy
loss before
14 wk
Delivery of a
live infant
after 24 wk
As soon as
pregnancy
conﬁrmed
Vaginal natural P
400 mg twice daily
Placebo Until
miscarriage
or the
12th wk
Miscarriage
Total – 1,399 (705/694) – – – – – –
Note: Data are presented as total number (n progestogens group/control group). GA ¼ gestational age.
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FIGURE 1
Forest plot for the risk of recurrent miscarriage in women with unexplained recurrent miscarriage. df ¼ degrees of freedom; M-H ¼ Mantel-
Haenszel.
Saccone. Progestogens for miscarriage. Fertil Steril 2016.
Fertility and Sterility®and 37 in the placebo group) and explicitly excluded women
who were receiving heparin therapy (24). Three studies re-
ported support or sponsorship from pharmaceutical com-
panies (19, 22, 26).
Synthesis of Results
Of the 1,586 women included in the meta-analysis, 802
(50.5%) were randomized to the intervention group, 784
(49.5%) to the control group. The pooled analysis of the pri-
mary outcome (i.e., incidence of miscarriage) is shown in
Figure 1. Women with a history of unexplained recurrent
miscarriage who were randomized to the intervention group
had a lower risk of recurrent miscarriage (RR 0.72, 95% CI
0.53–0.97; Fig. 1) and higher live birth rate (RR 1.07, 95%
CI 1.02–1.15) compared with those who did not. No statisti-
cally signiﬁcant differences were found in the other second-
ary outcomes, including preterm birth (RR 1.09, 95% CI
0.71–1.66), neonatal mortality (RR 1.80, 95% CI 0.44–7.34),
and fetal genital abnormalities (RR 1.68, 95% CI 0.22–
12.62). Statistical heterogeneity within the studies was
moderate for the primary outcome and low for the secondary
outcomes (Table 3).
Subgroup analysis of placebo-controlled trials (RR 0.80,
95% CI 0.70–0.97) (18, 19, 21, 22, 24, 26–28), oral
progestogens (RR 0.61, 95% CI 0.38–0.98) (18, 19, 25–27),
IM progestogens (RR 0.54, 95% CI 0.29–0.94) (21, 22, 28,
29), and synthetic progestogens (RR 0.35, 95% CI 0.23–0.52)
(18, 19, 21, 22, 25–28) concurred with the overall analysis.
However, no statistically signiﬁcant differences were found
in subgroup analyses of vaginal P (RR 0.96, 95% CI 0.79–
1.17) (24) or natural P (RR 0.94, 95% CI 0.77–1.13) (24, 29).
Five different type of progestogens were used: natural P,
medroxyprogesterone, cyclopentyl enol ether of P,
dydrogesterone, and 17-OHPC. However, pooled data were
available only for two types of progestins, 17-OHPC and dy-
drogesterone. Subgroup analyses of IM 17-OHPC (either dose
scale or 500 mg weekly) (21, 22, 28) and of oralVOL. 107 NO. 2 / FEBRUARY 2017dydrogesterone (either 2  5-mg tablet three times daily or
10 mg twice daily) (19, 25, 27) both concurred with the
overall analysis (RR 0.69, 95% CI 0.35–0.88; and RR 0.47,
95% CI 0.30–0.73, respectively). Subgroup analysis
according to deﬁnition of recurrent miscarriage supported
the overall analysis for trials in which recurrent miscarriage
was deﬁned as a history of three or more prior miscarriages
(RR 0.60, 95% CI 0.40–0.91) (24–29) but not for trials in
which recurrent miscarriage was deﬁned as a history of two
or more prior miscarriages (RR 1.14, 95% CI 0.62–2.09) (18,
19, 21, 22).
DISCUSSION
Main Findings
This meta-analysis from the 10 RCTs, including 1,586 women,
showed that progestogens in women with at least two or three
prior miscarriages were associated with lower risk of recurrent
miscarriages and seemed to be safe to use during the ﬁrst
trimester. Synthetic progestogens therapy but not natural P
supplementation was associated with a lower risk of recurrent
miscarriage. Notably, progestogens reduced the risk of
miscarriage in studies in which recurrent miscarriage was
deﬁned as a history of three or more miscarriages but not in
studies in which it was deﬁned as a history of two or more
miscarriages.Comparison with Existing Literature
Our meta-analysis supported earlier ﬁndings of a Cochrane
review (12) of four small trials (25, 26, 28, 29), showing a
signiﬁcantly lower risk of miscarriage among those who
received progestogens compared with placebo or no
treatment (odds ratio 0.39, 95% CI 0.21–0.72), whereas it
did not concur with a new large, well-designed RCT from
the United Kingdom (24). Indeed, Coomarasamy et al. (24)
showed that P therapy in the ﬁrst trimester of pregnancy
did not result in a signiﬁcantly higher rate of live births435
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ORIGINAL ARTICLE: EARLY PREGNANCYamong women with prior unexplained recurrent miscarriage.
However, they studied a vaginal preparation of P, at a dose of
400mg twice daily, whichmay be not generalizable to women
receiving other doses and preparations. Some studies indeed
have suggested that IM preparations of P and synthetic pro-
gestins may provide greater therapeutic effect than vaginal
and natural preparations, respectively (5, 30–32).Strengths and Limitations
Our study has several strengths. This meta-analysis included
all RCTs published to date on the topic. The number of
randomized women was high. To our knowledge, no prior
meta-analysis on this issue is as large, up to date, or compre-
hensive. We assessed the primary outcome in several sub-
group analyses, to reduce the clinical heterogeneity among
the trials. Intent-to-treat analysis was used, and both
random and ﬁxed effects models were used when appro-
priate. In addition, publication bias was not apparent by sta-
tistical analysis. Statistical heterogeneity among the studies
was variable but generally not signiﬁcant. These are key el-
ements that are needed to evaluate the reliability of a meta-
analysis (13).
Limitations of our study are inherent to the limitations
of the included RCTs. The ﬁrst and most important limita-
tion is the age of the included studies. Seven of the ten were
published before 1990; that is, before the days when ran-
domized trials had any chance of being conducted to any
degree of quality. This limitation raises the question of
the translation of these data to today's clinical manage-
ment and of the poor quality of the majority of the studies.
The PROMISE trial, the largest and most recent trial, re-
cruited more than the other trials put together and was
negative (24). Although this may be due to the use of nat-
ural P, the effect may have occurred because synthetic pro-
gestogens studies are older, generally smaller, and of lower
quality.
Only eight trials were double-blind. The studies span a
period of more than 60 years. Search strategies for retrieving
RCTs in electronic databases are limited, and this could have
inﬂuenced our ﬁndings. More than half of the women
included in the analysis (826 of the 1,586) came from one
large trial (24). The literature on P use can be divided into
replacement and supplementation. This meta-analysis fo-
cuses on supplementation. Further, different preparations,
routes, and doses of progestogens, as well as different dura-
tions of treatment, were used, so it is unclear which of these
should be preferred. This would only be effectively answered
with a head-to-head trial of different formulations, dosages,
and routes, although it does appear, as stated above, that the
synthetic, rather than natural, P preparations would be
preferred according to the literature to date. All the trials
initiated treatment after pregnancy was conﬁrmed, and
therefore our meta-analysis cannot address whether proges-
togens could be more effective if administered during the
luteal phase of the cycle, before the conﬁrmation of preg-
nancy (33–35). No trial reported long-term follow-up, so
the long-term safety of the intervention is still not well
known.VOL. 107 NO. 2 / FEBRUARY 2017
Fertility and Sterility®Implications
Progesterone is essential to achieve and maintain a healthy
pregnancy. It is known to induce secretory changes in the
lining of the uterus essential for successful implantation of
a fertilized egg (3, 4). It has been suggested that a
causative factor in many cases of miscarriage may be
inadequate secretion of P during the luteal phase of the
menstrual cycle and in the early weeks of pregnancy (1).
Therefore, progestogens have been used beginning in the
ﬁrst trimester of pregnancy in an attempt to prevent
spontaneous miscarriage (1, 12). Their use is particularly
common with assisted reproductive technologies (12, 31,
32). However, notably, it has been estimated that, in more
than half of miscarriages, a chromosomal abnormality is
present, and this could explain the percentage of
nonresponsive women (1, 12).
Progestogens can be classiﬁed as natural or synthetic
(30, 36). Natural compounds, including natural P, are those
with chemical structures similar to those produced by living
organisms. Synthetic progestogens (or progestins), including
17-OHPC, are compounds generated in the laboratory whose
structures have been modiﬁed and do not correspond to a
naturally occurring steroid (30, 36). Natural P and 17-OHPC
have different physiologic properties and pharmacologic pro-
ﬁles (30, 36) and therefore different indications for their use in
obstetrics and gynecology (5, 6, 10, 11, 30, 36–38). Natural P
suppresses myometrial contractility in strips that were
obtained at time of cesarean delivery, whereas 17-OHPC
does not have this effect and at high concentration stimulates
myometrial contractility. In pregnant animals and in vitro
experimentation, P but not 17-OHPC inhibits cervical
ripening. However, the effects of the two compounds are com-
plex and dependent on the route of administration and the
vehicle used (36). Luteal phase insufﬁciency is one of the rea-
sons for implantation failure and has been responsible for
miscarriage and unsuccessful assisted reproduction (29, 34).
Moreover, IM progestogens result in a higher plasma
concentration, and the level is maintained for a longer
duration compared with vaginally administered P (32).
Progesterone is essential for secretory transformation of the
endometrium that permits implantation and maintenance of
early pregnancy. Progestins have been shown to stimulate
the production of 34-KDa protein P-inducing blocking, which
prevents inﬂammatory reactions toward the trophoblast via
blockade of natural killer cells. Recently, several studies
showed that deregulation in the numbers of natural killer cells
and/or their activity in the blood and in the endometrium is
associated with various manifestations of reproductive failure
(29, 32, 34).
The fact that progestogens were associated with a lower
rate of recurrent miscarriage needs to be correlated also
with cost-effectiveness consideration. Unfortunately, none
of the included trials reported any cost or cost-effectiveness
analysis. The US cost of vaginal P (approximately $11 per
day, or approximately $77 per week) (39) is much lower
than that of 17-OHPC (approximately >$500 per week) (40).
In conclusion, our ﬁndings provide evidence that supple-
mentation with progestogens in the ﬁrst trimester of preg-VOL. 107 NO. 2 / FEBRUARY 2017nancy may reduce the incidence of miscarriages in women
with history of unexplained recurrent miscarriages. Synthetic
progestogens, including weekly IM 17-OHPC, but not natural
P were associated with a lower risk of recurrent miscarriage.
Given the limitations of the studies included in our meta-
analysis in terms of head-to-head comparisons, it is difﬁcult
to recommend a speciﬁc preparation, route, and dose of syn-
thetic progestogen therapy. Further head-to-head trials may
more fully address this question.REFERENCES
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SUPPLEMENTAL FIGURE 1
Flow diagram of studies identiﬁed in the systematic review (PRISMA
template).
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SUPPLEMENTAL FIGURE 2
Assessment of risk of bias. (A) Summary of risk of bias for each trial; Plus sign ¼ low risk of bias; minus sign ¼ high risk of bias; question mark ¼
unclear risk of bias. (B) Risk of bias graph about each risk of bias item presented as percentages across all included studies.
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SUPPLEMENTAL FIGURE 3
Funnel plot for assessing publication bias.
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